Alejandro D. Wellisch - 17 Feb 2023 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
SENIOR VICE PRESIDENT
Signature
/s/ Alejandro D. Wellisch by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
17 Feb 2023
Net transactions value
$0
Form type
4
Filing time
22 Feb 2023, 18:25:52 UTC
Previous filing
02 Mar 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +31,236 $0.000000 31,236 17 Feb 2023 Common Shares 31,236 $106.24 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 10,412 on February 17, 2024, 10,412 on February 17, 2025, and 10,412 on February 17, 2026.